Related Experiment Video
Updated: Jun 30, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Coronary drug-eluting stents in diabetic patients]
Astrid Nyssen1, Victor Legrand, André J Scheen
1Service de cardiologie, Département de médecine CHU de Liège, Sart Tilman, 4000 Liège, Belgique.
Abstract:
In diabetic patients, the use of drug-eluting stents (paclitaxel-PES or sirolimus-SES) reduces the risk of restenosis as compared to bare-metal stents. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents. All together, the incidence of major cardiovascular events is reduced with drug-eluting stents, mainly resulting from a diminution of revascularisation procedures rather than from a reduction in myocardial infarcts or cardiovascular deaths. Attempts to compare SES and PES gave discordant results in both randomised trials and registries. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Diabetic Retinopathy
Diabetic Foot Ulcer
Diabetic Nephropathy
Coronary Artery Disease IV: Preventive Measures
Complications of Diabetes Mellitus